These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

132 related articles for article (PubMed ID: 35139518)

  • 1. Topical Rosmarinus officinalis L. in Systemic Sclerosis-Related Raynaud's Phenomenon: An Open-Label Pilot Study.
    Vagedes J; Henes J; Deckers B; Vagedes K; Kuderer S; Helmert E; von Schoen-Angerer T
    Complement Med Res; 2022; 29(3):242-248. PubMed ID: 35139518
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Effect of topical rosemary essential oil on Raynaud phenomenon in systemic sclerosis.
    von Schoen-Angerer T; Deckers B; Henes J; Helmert E; Vagedes J
    Complement Ther Med; 2018 Oct; 40():191-194. PubMed ID: 30219447
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Fish-oil dietary supplementation in patients with Raynaud's phenomenon: a double-blind, controlled, prospective study.
    DiGiacomo RA; Kremer JM; Shah DM
    Am J Med; 1989 Feb; 86(2):158-64. PubMed ID: 2536517
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Measurement of cold challenge responses in primary Raynaud's phenomenon and Raynaud's phenomenon associated with systemic sclerosis.
    O'Reilly D; Taylor L; el-Hadidy K; Jayson MI
    Ann Rheum Dis; 1992 Nov; 51(11):1193-6. PubMed ID: 1466594
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Prospective, open-label, uncontrolled pilot study to study safety and efficacy of sildenafil in systemic sclerosis-related pulmonary artery hypertension and cutaneous vascular complications.
    Kumar U; Sankalp G; Sreenivas V; Kaur S; Misra D
    Rheumatol Int; 2013 Apr; 33(4):1047-52. PubMed ID: 22833239
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Botulinum toxin type A contribution in the treatment of Raynaud's phenomenon due to systemic sclerosis].
    Serri J; Legré R; Veit V; Guardia C; Gay AM
    Ann Chir Plast Esthet; 2013 Dec; 58(6):658-62. PubMed ID: 22204894
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Oral iloprost in Raynaud's phenomenon secondary to systemic sclerosis: a multicentre, placebo-controlled, dose-comparison study.
    Black CM; Halkier-Sørensen L; Belch JJ; Ullman S; Madhok R; Smit AJ; Banga JD; Watson HR
    Br J Rheumatol; 1998 Sep; 37(9):952-60. PubMed ID: 9783759
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Differences in red cell behaviour between patients with Raynaud's phenomenon and systemic sclerosis and patients with Raynaud's disease.
    Rustin MH; Kovacs IB; Sowemimo-Coker SO; Maddison PJ; Kirby JD
    Br J Dermatol; 1985 Sep; 113(3):265-72. PubMed ID: 3877518
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Plasma adrenomedullin and endothelin-1 levels are reduced and Raynaud's phenomenon improved by daily tadalafil administration in male patients with systemic sclerosis.
    Rosato E; Letizia C; Proietti M; Aversa A; Menghi G; Rossi C; Torella E; Cotesta D; Petramala L; Bruzziches R; Spera G; Pisarri S; Salsano F
    J Biol Regul Homeost Agents; 2009; 23(1):23-9. PubMed ID: 19321043
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A randomised double-blind trial of diltiazem in the treatment of Raynaud's phenomenon.
    Kahan A; Amor B; Menkes CJ
    Ann Rheum Dis; 1985 Jan; 44(1):30-3. PubMed ID: 3882061
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Raynaud's phenomenon.
    Devgire V; Hughes M
    Br J Hosp Med (Lond); 2019 Nov; 80(11):658-664. PubMed ID: 31707892
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Serial computed thermography for Raynaud's phenomenon of patient with progressive systemic sclerosis (PSS)].
    Tomono N; Kuriyama T; Mori M; Takahashi Y; Mitsuda T; Aihara Y; Yokota S
    Ryumachi; 1996 Jun; 36(3):522-7. PubMed ID: 8779789
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Intravenous iloprost treatment of Raynaud's phenomenon and ischemic ulcers secondary to systemic sclerosis.
    Wigley FM; Seibold JR; Wise RA; McCloskey DA; Dole WP
    J Rheumatol; 1992 Sep; 19(9):1407-14. PubMed ID: 1279170
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Responses to nifedipine by patients with Raynaud's disease and Raynaud's phenomenon secondary to another disease.
    Riccio A; Del Puente A; Farinaro C; Scarpa R; Oriente P; Rocco P; Gioia M
    Clin Ther; 1987; 9(2):232-7. PubMed ID: 3568066
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Raynaud's phenomena: diagnostic and treatment study].
    Priollet P
    Rev Prat; 1998 Oct; 48(15):1659-64. PubMed ID: 9814067
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effect of clonazepam on Raynaud's phenomenon and fingertip ulcers in scleroderma.
    Colakoğlu M; Cobankara V; Akpolat T
    Ann Pharmacother; 2007 Sep; 41(9):1544-7. PubMed ID: 17666574
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Raynaud's phenomenon and systemic sclerosis.
    Generini S; Kahaleh B; Matucci-Cerinic M; Pignone A; Lombardi A; Ohtsuka T
    Ann Ital Med Int; 1996; 11(2):125-31. PubMed ID: 8974438
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Increased urinary pyridinoline cross-link compounds of collagen in patients with systemic sclerosis and Raynaud's phenomenon.
    Istok R; Czirják L; Lukác J; Stancíková M; Rovenský J
    Rheumatology (Oxford); 2001 Feb; 40(2):140-6. PubMed ID: 11257149
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Efficacy of beraprost sodium on Raynaud's phenomenon in patients with systemic sclerosis].
    Kaburaki J; Kuwana M; Akizuki M; Takano M; Tojo T
    Nihon Rinsho Meneki Gakkai Kaishi; 1995 Feb; 18(1):29-35. PubMed ID: 7553036
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Nifedipine in the treatment of Raynaud's phenomenon in patients with systemic sclerosis.
    Meyrick Thomas RH; Rademaker M; Grimes SM; MacKay A; Kovacs IB; Cook ED; Bowcock SM; Kirby JD
    Br J Dermatol; 1987 Aug; 117(2):237-41. PubMed ID: 3307894
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.